ESTRO 38 Abstract book

S809 ESTRO 38

reviewed. From 2010 to 2018, a total of 49 patients with single or multiple metastases for a total of 96 lesions were treated in our Center. Primary cancer were 33 ovarian, 10 endometrial, 4 cervical, 1 vulvar and 1 tubal cancer. Toxicities were graded according to Common Terminology Criteria for Adverse Events version 4.0. Tumor response was evaluated by CT/ PET and/or MRI, according to Response Evaluation Criteria in Solid Tumors (version 1.1) Results Median follow-up was 24 months (range 6-100). Most of treated lesions were located in lymph nodal sites 54.2%, lung in 22.9%, liver in 20.8% of cases, and soft tissue in 2.1%. Complete radiologic response, partial response, stable disease and progressive disease were observed in 57.3%, 26%, 10.4% and 6.3% of cases, respectively.The median LC was not reached. One year- and three year- LC were 96.6%. Median distant control was 35.5 months. Median OS was 59.9 months. All of patients completed the prescribed treatment with a low toxicity profile: only 12.5% experienced G2 acute toxicity, most common adverse effect was abdominal pain (5.2%), fatigue (4.2 %) and nausea and vomiting (3.1%). None of the patients had grade 3 or 4 acute or late toxicity. Conclusion SBRT is a feasible and safe approach in selected cases of oligometastatic gynecological cancer with satisfactory results in terms of LC and DFS. EP-1494 Quality of life in women treated for gynecologic malignancies and dose-volume parameters correlation A. Caroli 1 , L. Masini 1 , C. Pisani 1 , E. Gallizia 1 , I. Luciani 1 , M. Brambilla 2 , M. Krengli 1 1 Hospital Maggiore della Carità, Department of Radiotherapy, Novara, Italy ; 2 Hospital Maggiore della Carità, Medical Physics, Novara, Italy Purpose or Objective The purpose of this study was to assess self-reported overall QoL and QoL related to genito-urinary and gastroenteric symptoms in patients affected by endometrial and cervical cancer after radiation therapy and in regular follow-up and to analyze a possible correlation with dose–volume parameters of organ at risks (OARs) Material and Methods We administered the anonymous EORTC QLQ-C30 to 182 patients, 141 with endometrial cancer and 41 with cervical cancer, treated with pelvic radiotherapy from 2011 to 2017 and in regular follow-up in our center. The questionnaire was combined with EORT QLQ-EN24, in case of endometrial cancer, or with EORT QLQ-CX 24, in case of cervical cancer. There were no limitations regarding age or performance status. We analyzed overall health and overall quality of life (score from zero (low QoL) to seven (high QoL)), bladder symptoms, dysuria, bladder incontinence and fecal incontinence and their correlation with dose–volume parameters of OARs (whole bladder, bladder trigone, rectum and lumbosacral plexus). Results QoL was very high (score 6-7) in many patients (88.5 % of patients). Relatively few patients referred urinary incontinence (12.6 %) or abdominal discomfort of high grade (7.2 %). We found a significant correlation between bladder V35, i.e., absolute percentage of bladder volume that received a dose of 35 Gy, and urinary incontinence (p<0.05, R=0.27, R2 = 0.06), and abdominal pain (p<0.05, R= 0.16, R2 = 0.02). We found also a correlation between urinary urgency and bladder V40, i.e., absolute percentage of bladder volume that received a dose of 40 Gy (p<0.05, R= 0.22, R2 = 0.06). Conclusion Women treated with surgery and radiotherapy for endometrial and cervical cancers have good QoL with

Conclusion These findings support IMRT as a safe technique for the treatment of endometrial cancer with no difference in efficacy and an apparently lower incidence of acute GI toxicities. Results of long-term prospective trials are needed to confirm these results. EP-1493 SBRT for oligometastatic gynecological cancer: a single institution experience C. Iftode 1 , A. Tozzi 1 , G.R. D'Agostino 1 , T. Comito 1 , C. Franzese 1 , F. De Rose 1 , D. Franceshini 1 , L. Di Brina 1 , P. Navarria 1 , E. Clerici 1 , S. Tomatis 1 , M. Scorsetti 1 1 Humanitas Research Hospital, Radiotherapy and Radiosurgery, Rozzano Milan, Italy Purpose or Objective The aim of this study was to evaluate the role of stereotactic body radiotherapy (SBRT) in a series of oligometastatic gynecological malignancies. Material and Methods Clinical records of patients affected by oligometastatic of any gynecological carcinoma treated with SBRT were